Navigation Links
AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress
Date:10/15/2007

Company Prices New HIV/AIDS Salvage Drug at $9,900 USD Per Patient Yearly Following FDA's Recent Approval of Isentress, Merck's New Integrase Inhibitor. AHF Decries Overall Price Spiral on New AIDS Drugs; Urges Restraint by Entire Pharmaceutical Industry in Pricing

LOS ANGELES, Oct. 15 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today criticized Merck and Co. Pharmaceuticals, for the announced price for its key new HIV/AIDS drug, Isentress (raltegravir), an integrase inhibitor approved by the Food and Drug Administration (FDA) Friday, and priced by the company at nearly $9,900 per patient yearly. Today's Kaiser Daily HIV/AIDS Report noted that Isentress is an integrase inhibitor that "...decreases HIV viral loads after 24 weeks of use among HIV-positive people who have not responded to other treatments," according to a study published in the April 14 online edition of the journal Lancet."

"We commend Merck for the development of this new HIV/AIDS drug that shows particular promise as a salvage therapy, but urge the company to reconsider its action and set the price of this lifesaving medicine so it is affordable," said Michael Weinstein, AIDS Healthcare Foundation President. "The steep cost of this new drug is symptomatic of the overall price spiral of AIDS drugs. As with many other AIDS drugs before it, the price is simply out of reach for most AIDS patients, and Merck and other companies' pricing for their AIDS drugs threatens to further limit the ability of Medicaid and AIDS Drug Assistance Programs nationwide to provide crucial medications to its patient populations."

According to a Reuters news article, "The company (Merck) said it would charge about $27 per day, or $9,855 annually, for the drug. Steep prices for AIDS drugs have been criticized by patients and advocacy groups, who say they deter use of lifesaving drugs."

In 2004, Roche & Trimeris created an international uproar when its drug Fuzeon, also widely used as a second or third-line salvage therapy, was first introduced and priced at $20,000 USD per year, per patient--far above what analysts had expected.

AHF's Weinstein added, "AIDS drugs are priced at the maximum the market will bear, regardless of production costs. Other drug makers continue to follow suit with equally high prices, and access to care and treatment is the casualty. We challenge both Merck and the pharmaceutical industry as a whole to set pricing and access policies for these potentially lifesaving AIDS drugs in a manner that illustrates its concern for patient quality of life, rather than contributing to the public's growing crisis of confidence in it."

About AHF

AIDS Healthcare Foundation (AHF) is the US' largest non-profit HIV/AIDS healthcare, research, prevention and education provider. AHF currently provides medical care and/or services to more than 61,000 individuals in 15 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at http://www.aidshealth.org


'/>"/>
SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Momentum of Stem cell research impeded by legal challenges
2. Australia Ready to Meet the Challenges of Bird Flu
3. Sexual Health Service Is Under Pressure and Faced With Financial Challenges
4. Abuja Challenges the Government
5. Nurses in South Africa Face Challenges
6. Bangladesh Progressing But Must Yet Face Challenges In Health Sector
7. Fresh Water, HIV Biggest of Indias Six Challenges: Chidambaram
8. New Study Challenges How Regulators Determine Risk
9. FDA Cites Challenges of Generic Biotech
10. Study Challenges Conventional Treatment of Traumatic Brain Injury
11. Challenges in Entecavir Drug Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: